OVERVIEW

Updates on Blood Cholesterol: Applying New Guidelines to Clinical Practice is organized by Rockpointe Corporation.

Release date: September 24, 2019
Expiration date: September 24, 2020

Accreditation:
Physician Credit Designation?
The National Lipid Association designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists Credit Designation
This activity has been approved for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

Nurses Credit Designation
The maximum number of hours awarded for this CE activity is 1.3 contact hours.

Overview:
Cardiovascular disease is the leading cause of death in the US. While tools have been developed to identify patients at increased risk for atherosclerotic cardiovascular disease (ASCVD), these instruments are not always used in clinical practice. To improve the identification of at-risk patients, in late 2018 the American Heart Association (AHA) and American College of Cardiology (ACC) jointly published guidelines for the use of risk-assessment tools.

In November 2018, the AHA, ACC, and other partnering associations also released a “Guideline on the Management of Blood Cholesterol” to provide updated clinical recommendations for the management of elevated low-density lipoprotein cholesterol (LDL-C), a major contributor to ASCVD.This document provided strategies for primary and secondary prevention of ASCVD, along with approaches for modifying therapy in patients who are not achieving their LDL-C goals.

This activity, Updates on Blood Cholesterol: Applying New Guidelines to Clinical Practice, will review these recent evidence-based recommendations and updates, as well as providing information about non-statin agents recommended for use when patients are not at LDL-C goal.

Educational Objectives:
At the conclusion of this activity, participants should be able to:
• Use guideline-recommended tools to evaluate the need for blood cholesterol management for primary ASCVD prevention in patients without clinical ASCVD
• Implement the 2018 cholesterol guidelines when developing individualized primary prevention strategies for patients with and without severe hypercholesterolemia
• Develop management plans for the secondary prevention of ASCVD using recommendations from the 2018 blood cholesterol guidelines
• Intensify LDL-C management using adjunctive non-statin therapy when secondary prevention with statins alone does not achieve 2018 blood cholesterol guideline goals